These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 15059898)
1. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898 [TBL] [Abstract][Full Text] [Related]
2. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517 [TBL] [Abstract][Full Text] [Related]
3. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414 [TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298 [TBL] [Abstract][Full Text] [Related]
5. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210 [TBL] [Abstract][Full Text] [Related]
6. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Becker K; Pancoska P; Concin N; Vanden Heuvel K; Slade N; Fischer M; Chalas E; Moll UM Int J Oncol; 2006 Oct; 29(4):889-902. PubMed ID: 16964385 [TBL] [Abstract][Full Text] [Related]
7. The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas. Domínguez G; Peña C; Silva J; García JM; García V; Rodríguez R; Cantos B; Citores MJ; España P; Bonilla F J Pathol; 2006 Dec; 210(4):390-7. PubMed ID: 17029218 [TBL] [Abstract][Full Text] [Related]
8. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Soldevilla B; Díaz R; Silva J; Campos-Martín Y; Muñoz C; García V; García JM; Peña C; Herrera M; Rodriguez M; Gómez I; Mohamed N; Marques MM; Bonilla F; Domínguez G Clin Cancer Res; 2011 Sep; 17(18):6029-39. PubMed ID: 21807636 [TBL] [Abstract][Full Text] [Related]
10. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Petrenko O; Zaika A; Moll UM Mol Cell Biol; 2003 Aug; 23(16):5540-55. PubMed ID: 12897129 [TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature. Hofstetter G; Berger A; Chamson M; Müller-Holzner E; Reimer D; Ulmer H; Uramoto H; Marth C; Zeimet AG; Zeillinger R; Concin N Int J Gynecol Pathol; 2011 Nov; 30(6):527-31. PubMed ID: 21979586 [TBL] [Abstract][Full Text] [Related]
12. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells. Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538 [TBL] [Abstract][Full Text] [Related]
13. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression. Saifudeen Z; Diavolitsis V; Stefkova J; Dipp S; Fan H; El-Dahr SS J Biol Chem; 2005 Jun; 280(24):23094-102. PubMed ID: 15805112 [TBL] [Abstract][Full Text] [Related]
14. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Stiewe T; Tuve S; Peter M; Tannapfel A; Elmaagacli AH; Pützer BM Clin Cancer Res; 2004 Jan; 10(2):626-33. PubMed ID: 14760085 [TBL] [Abstract][Full Text] [Related]
15. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511 [TBL] [Abstract][Full Text] [Related]
16. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. Di Vinci A; Sessa F; Casciano I; Banelli B; Franzi F; Brigati C; Allemanni G; Russo P; Dominioni L; Romani M Int J Oncol; 2009 Feb; 34(2):449-56. PubMed ID: 19148480 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis. Buhlmann S; Racek T; Schwarz A; Schaefer S; Pützer BM J Mol Biol; 2008 Apr; 378(1):20-30. PubMed ID: 18342333 [TBL] [Abstract][Full Text] [Related]
18. Generation of DeltaTAp73 proteins by translation from a putative internal ribosome entry site. Sayan AE; Roperch JP; Sayan BS; Rossi M; Pinkoski MJ; Knight RA; Willis AE; Melino G Ann N Y Acad Sci; 2007 Jan; 1095():315-24. PubMed ID: 17404044 [TBL] [Abstract][Full Text] [Related]